Arising from paper presented to Section of Anaesthetics. 10January 1986 0141-0768/87/ 030136·02/$02.00/0 e 1987 The Royal Society of Medicine Calcium, its agonises and antagonists: past, present and future Calcium ions play an essential and ubiquitous role in mediating physiological mechanisms. Fundamental cellular processes such as endocytosis, exocytosis, cellular mobility and cell division are all mediated by calcium ions. Specific mechanisms in which calcium plays a key role as a second messenger vary from coupling excitation to contraction in muscle to mediating hormone and neurotransmitter secretion, the metabolism of glycogen. and blood coagulation and haemostasis. The first report on the essential physiological role of this small, doubly charged ion was made by Professor Sydney Ringer of University College, London, who in November 1882 observed that calcium was necessary to maintain contraction of heart muscle. Like so many crucial observations made in science, Ringer's owed more to serendipity than critical inquiry. After publication of a paper entitled •Concerning the influence exerted by each of the constituents of the blood on the contraction of the ventricle", he discovered that the saline solution which he had used had not been prepared with distilled water, but with pipe water supplied by the New River Water Company: 'As this water contains minute traces of various inorganic substances. I at once tested the action of saline solution made with distilled water and I found that I did not get the effects described in the paper referred to. It is obvious. therefore. that the effects 1 had obtained are due to some of the inorganic constituents of the pipe water'. 2 The pipe water was analysed and found to contain 38 parts pel' million of calcium, and Ringer was able to show conclusively that calcium was necessary to maintain cardiac contraction. 'I find that calcium. in the form oflime water, or bicarbonate of lime or chloride of calcium, even in minute doses, produces the changes in the ventricle'. 2
The last twenty years have seen an enormous increase in our understanding of the unique role of calcium as a second messenger linking fundamental physiological mechanisms. Its pre-eminent role as the primary intracellular messenger is due to the fact that it is a small ion (with a similar radius to sodium) but it has a double charge and is therefore capable of binding tightly to other compounds. It is the intracellular calcium fraction that is crucial to the numerous processes in which calcium is involved, although the concentration of the ion is about 10 000 times higher in the extracellular fluid than it is inside the cell. Intracellular calcium does not act in its free form but requires a binding protein to modulate its actions. Calmodulin is the commonest receptor protein. and its existence was reported independently from the USA 3 and -Iapan" in 1970.It has four binding sites for calcium and regulates numerous cellular functions. It interacts particularly with enzymes which catalyse phosphorylation -a key regulatory factor in enzymatic activity. In skeletal muscle, for example, calcium-activated calmodulin in turn activates a protein kinase that phosphorylates a second enzyme, which in its turn is then activated to catalyse the breakdown of glycogen to provide energy for muscular work.
Another important chance observation was made in November 1963 by Albrecht Fleckenstein at Freiburg University in Germany when studying the unexplained cardiodepressant side effects of two newly synthesized coronary vasodilators. ' The discovery of Ca + + antagonism occurred by chance. To our surprise, it rapidly became evident that both compounds [prenylamine and verapamil] mimicked the cardiac effects of simple Ca + + withdrawal." It was clear from Fleckenstein's early work that the agents were restricting the calcium supply to the myocardial contractile fibres, but it was not until the clamping techniques described by Reuter and Beeler", which allowed for the separation of transmembrane sodium and calcium currents, that the relatively specific effect of these agents on the inward calcium current became recognized. In 1969 Fleckenstein and his colleagues designated these compounds 'calcium antagonists' and a new pharmacodynamic principle was born. Calcium antagonists have been widely used in the past decade not only in therapeutics but also in physiology as a means of investigating calcium channels.
Current evidence proposes that there are at least four different types of calcium entry mechanism or 'channels". These have been designated leak channels, stretch-sensitive channels, potential-dependent channels and receptor-dependent channels. The two former 'channels' are unlikely to be classical gated channels as such, but probably represent mechanisms of calcium influx so-termed for convenience. The latter mechanisms have been more clearly defined, the potential-dependent channel having been extensively studied. Its existence as an ion-specific gated channel is now beyond dispute 7 • Specific calcium antagonists (or channel blockers as they are sometimes termed) are a heterogeneous group of drugs with diverse chemical structures. There is no doubt that they do not act in precisely the same manner and all may inhibit calcium at sites other than specific gated channels. It has been suggested that these drugs may act, in part at least, by inhibiting the interaction of calcium with its receptor proteins such as calmodulin". The significance ofthis has been questioned 7 and it seems probable that this is a concentration-dependent effect. However, there is no doubt that individual calcium antagonists have a variety of effects and there is now convincing evidence that one of the most recently introduced drugs, diltiazem, binds to the plasma membrane at a site quite distinct from that of nifedipine 9 • The drugs currently available (verapamil, nifedipine and diltiazem) are principally used in the treatment of cardiovascular diseases. They each have a different spectrum of influence on heart muscle (negative inotropic effect), impulse generation and conduction in the heart (negative chronotropic and dromotropic effect) and vascular tone (peripheral and coronary vasodilatation). Thus verapamil markedly slows atrioventricular nodal conduction (duration of action potential is calcium-dependent), unlike nifedipine, and the former has useful antidysrhythmic properties which the latter lacks. Because they reduce the principal determinants of myocardial oxygen demand (contractility and 'afterload') whilst improving supply (coronary vasodilatation), they have become widely used in the treatment of angina pectoris -both exertional and variant -and have also become first-line drugs in the treatment of arterial hypertension. For any patients at risk, drugs such as nifedipine are better tolerated than beta-adrenergic antagonists: this is especially so in patients with variant angina, peripheral vascular disease, obstructive airways disease or impaired left ventricular function.
Drugs with a more specific site of action are currently undergoing extensive clinical trials. An example is nicardipine, which is a dihydropyridine chemically related to nifedipine. The agent has no effect on the conduction system and appears more selective for smooth muscle than nifedipine, and in therapeutic doses has been reported to have little or no negative inotropic effect!", This brings us to a consideration of the future for this relatively new class of drug. Drugs capable of specifically inhibiting calcium in bronchial smooth muscle would be of value in asthma and the potential role of these drugs has been the topic of a recent review ' l . Although convincing clinical evidence is still lacking, there is strong pathophysiological evidence that calcium antagonists might be expected to reduce myocardial infarct size. There is also convincing experimental work to suggest that calcium antagonists, even administered as post-ischaemic intervention, are effective in reducing ischaemic cerebral damage!", Certainly, the therapeutic importance and application of calcium antagonists will continue to increase. Further, in the future there is the prospect ofinhibiting atherosclerosis and other ageing processes. A number of groups of researchers have reported that the calcification of blood vessels of ageing rats l 3 and rabbits!" can be inhibited by long-term calcium antagonist therapy.
Finally, calcium channel activators or (calcium agonists) have recently been described which have led to a further appreciation of the mechanisms and drug modulation of calcium gated channels. One such agent, related to nifedipine chemically, is BAY K 8644. This has been shown to increase calcium flux through potential-dependent channels and to have positive inotropic and vasoconstricting properties 7 • Agents such as this might have value not only in the treatment of heart failure, but also (because calcium mediates hormone release) in a variety of endocrino-Journal of the Royal Society of Medicine Volume 80 March 1987 137 logical disorders. As is so often the case in medicine, advances in physiology lead to advances in therapeutics which in turn can be used further to increase our understanding of physiological events. In terms of the physiology of calcium and the therapeutic application of antagonists and agonists, this cycle of events promises to be a most rewarding one for scientist, physician and patient alike.
